Stockreport

Candel Therapeutics Announces $80 Million Proposed Public Offering

Candel Therapeutics, Inc.  (CADL) 
PDF NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing [Read more]